It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mutations in the SNCA gene cause autosomal dominant Parkinson’s disease (PD), with loss of dopaminergic neurons in the substantia nigra, and aggregation of α-synuclein. The sequence of molecular events that proceed from an SNCA mutation during development, to end-stage pathology is unknown. Utilising human-induced pluripotent stem cells (hiPSCs), we resolved the temporal sequence of SNCA-induced pathophysiological events in order to discover early, and likely causative, events. Our small molecule-based protocol generates highly enriched midbrain dopaminergic (mDA) neurons: molecular identity was confirmed using single-cell RNA sequencing and proteomics, and functional identity was established through dopamine synthesis, and measures of electrophysiological activity. At the earliest stage of differentiation, prior to maturation to mDA neurons, we demonstrate the formation of small β-sheet-rich oligomeric aggregates, in SNCA-mutant cultures. Aggregation persists and progresses, ultimately resulting in the accumulation of phosphorylated α-synuclein aggregates. Impaired intracellular calcium signalling, increased basal calcium, and impairments in mitochondrial calcium handling occurred early at day 34–41 post differentiation. Once midbrain identity fully developed, at day 48–62 post differentiation, SNCA-mutant neurons exhibited mitochondrial dysfunction, oxidative stress, lysosomal swelling and increased autophagy. Ultimately these multiple cellular stresses lead to abnormal excitability, altered neuronal activity, and cell death. Our differentiation paradigm generates an efficient model for studying disease mechanisms in PD and highlights that protein misfolding to generate intraneuronal oligomers is one of the earliest critical events driving disease in human neurons, rather than a late-stage hallmark of the disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 The Francis Crick Institute, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830); UCL Queen Square Institute of Neurology, Queen Square, Department of Clinical and Movement Neurosciences, London, UK (GRID:grid.436283.8) (ISNI:0000 0004 0612 2631); Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, USA (GRID:grid.513948.2) (ISNI:0000 0005 0380 6410)
2 The Francis Crick Institute, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830); UCL Queen Square Institute of Neurology, Queen Square, Department of Clinical and Movement Neurosciences, London, UK (GRID:grid.436283.8) (ISNI:0000 0004 0612 2631)
3 The Francis Crick Institute, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830)
4 Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, USA (GRID:grid.513948.2) (ISNI:0000 0005 0380 6410); University of Dundee, Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, Dundee, UK (GRID:grid.8241.f) (ISNI:0000 0004 0397 2876)
5 University of Edinburgh, EaStCHEM School of Chemistry, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); University of Edinburgh, Center for Regenerative Medicine, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
6 University of Edinburgh, EaStCHEM School of Chemistry, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
7 UCL Queen Square Institute of Neurology, Department of Clinical and Experimental Epilepsy, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
8 UCL Great Ormond Street Institute of Child Health, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
9 UCL Queen Square Institute of Neurology, Queen Square, Department of Neurodegenerative Diseases, London, UK (GRID:grid.436283.8) (ISNI:0000 0004 0612 2631)
10 UCL Queen Square Institute of Neurology, Queen Square, Department of Clinical and Movement Neurosciences, London, UK (GRID:grid.436283.8) (ISNI:0000 0004 0612 2631)
11 Rowett Institute, University of Aberdeen, Aberdeen, UK (GRID:grid.7107.1) (ISNI:0000 0004 1936 7291)
12 University of Edinburgh, Center for Regenerative Medicine, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
13 The Francis Crick Institute, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830); UCL Queen Square Institute of Neurology, Queen Square, Department of Neuromuscular Disease, London, UK (GRID:grid.436283.8) (ISNI:0000 0004 0612 2631)